Skip to main content
. 2022 Feb 15;66(2):e00916-21. doi: 10.1128/aac.00916-21

FIG 1.

FIG 1

Study design. HIV, human immunodeficiency virus; N(t)RTIs, nucleos(t)ide analogue reverse transcriptase inhibitor; PK, pharmacokinetics; q.d., once daily; RPV, rilpivirine.